US Patent Application 20090263421 - CELLULAR VACCINE
InventorsUS Classes424/209.1, Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.)424/93.71, Leukocyte424/204.1, Virus or component thereof424/225.1, Hepatitis virus (e.g., infectious canine hepatitis virus, duck hepatitis virus, mouse hepatitis virus, etc.)424/226.1, Hepatitis A virus424/227.1, Hepatitis B virus (e.g., hepatitis B surface antigen (HBsAg), pre-S region, hepatitis B core antigen (HBcAg), hepatitis B e-antigen, Dane particle, etc.)424/224.1, Rhabdoviridae (e.g., rabies virus, vesicular stomatitis virus, etc.)424/232.1, Poxviridae (e.g., smallpox virus, avian pox virus, fowlpox virus, rabbit myxoma virus, vaccinia virus, etc.)424/234.1, Bacterium or component thereof or substance produced by said bacterium (e.g., Legionella, Borrelia, Anaplasma, Shigella, etc.)424/263.1, Chlamydia (e.g., Chlamydia trachomatis, etc.)424/249.1, Neisseria (e.g., Neisseria gonorrhoeae, etc.)424/256.1Hemophilus (e.g., Hemophilus influenzae, Hemophilus gallinarum, Hemophilus pleuropnemoniae, etc.)Attorney, Agent or FirmInternational ClassesA61K 39/145A61K 45/00 A61K 39/12 A61K 39/29 A61K 39/205 A61K 39/275 A61K 39/02 A61K 39/118 A61K 39/095 A61K 39/102 A61P 37/04 Abstract textThe present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. In addition, the invention provides a composition having microbicide activity, or capable thereof upon exposure to antigen-presenting cells, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. Also provided by the present invention are methods for making and using the vaccines and compositions described herein. |
| ||||||||||||||
